Transgenic overexpression of a dominant negative Rho-kinase/ROCK2 (DN-RhoK), which inhibits ROCK1 and ROCK2 function, led to significantly fewer changes in pressure-loaded ventricles and improved survival in both PAC and TAC models. Here, ROCK1 is linked to persistent truncus arteriosus.